Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07681596 · ClinicalTrials.gov registry record · Phase 1
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by AstraZeneca.
- Not yet
- Registry status
- Phase 1
- Development phase
- 101
- Enrollment target
NCT07681596: Clinical Trial Phase 1 study, sponsored by AstraZeneca.
NCT07681596 is a Phase 1 study that has not yet begun recruiting, run by AstraZeneca. The registered enrollment target is 101 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07681596, a Phase 1 study, has not yet begun recruiting, sponsored by AstraZeneca.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 101 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.
Primary Outcome
Incidence and severity of adverse events (AEs) and serious AEs (SAEs)
Interventions
- DRUG Aldesleukin
- DRUG Daratumumab
- BIOLOGICAL AZD4045
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2026-07-09 |
| Est. Completion | 2029-10-30 |
| Phase | Phase 1 |
What is known before NCT07681596 opens enrollment
NCT07681596 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% higher).
The record links to 0 conditions, and to 3 interventions - of which Aldesleukin is the first listed.
NCT07681596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07681596 about?
NCT07681596 is a clinical study titled "A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.
What is the current status of trial NCT07681596?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2026-07-09. Estimated completion is 2029-10-30.
What interventions are being tested in trial NCT07681596?
The interventions under investigation include: Aldesleukin (DRUG), Daratumumab (DRUG), AZD4045 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07681596?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07681596's enrollment target sits among peer trials
101 546th of 2000 higher than 1,455 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI